FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2078797427> ?p ?o ?g. }

• W2078797427 endingPage "27" @default.
• W2078797427 startingPage "20" @default.
• W2078797427 abstract "To evaluate pregabalin (PGB), 150 mg/day, and PGB, 600 mg/day, as an add-on treatment for patients with refractory partial seizures concurrently treated with one to three anticonvulsants (AEDs).An international (13 countries), multicenter (45 centers), 12-week, double-blind, randomized study in which patients with partial seizures received placebo (n = 96); PGB, 150 mg/day (n = 99); or PGB, 600 mg/day (n = 92); given 3 times a day (t.i.d.). The primary efficacy criterion was reduction in seizure frequency during treatment as compared with baseline, as measured by RRatio, the symmetrical percentage change in seizure rates determined from daily seizure diaries. The RRatio between the 8-week baseline (pretreatment phase) and the 12-week treatment period were compared between each of the PGB groups and the placebo group by using an analysis of variance analysis of the intent-to-treat population.PGB, 150 mg/day and 600 mg/day, were both significantly more effective than placebo in reducing the RRatio [-11.5 (p = 0.0007) and -31.4 (p < or = 0.0001), respectively, vs. 0.9]. These RRatio values correspond to seizure-frequency reductions from baseline of -1.8, 20.6, and 47.8% for placebo, 150 mg/day, and 600 mg/day, respectively. PGB efficacy was significantly dose related (p < or = 0.0001). Secondary efficacy variables corroborated the findings of the primary analysis. Significantly more patients were responders (> or =50% reduction in seizure frequency) in the PGB, 600 mg/day (43.5%), group than in the placebo group (6.2%) (p < or = 0.001). PGB was well tolerated. Dose-related, treatment-emergent adverse events (> or =10%), mostly mild or moderate in intensity, were somnolence, dizziness, ataxia, diplopia, and weight gain. The withdrawal rate due to adverse events was 10% of patients at 150 mg/day and 18.5% of patients at 600 mg/day, compared with 6.2% of patients receiving placebo.PGB, 150 mg/day and 600 mg/day, is highly effective and well-tolerated add-on therapy in patients with partial seizures." @default.
• W2078797427 created "2016-06-24" @default.
• W2078797427 creator A5020080352 @default.
• W2078797427 creator A5040362413 @default.
• W2078797427 creator A5052872325 @default.
• W2078797427 creator A5054298959 @default.
• W2078797427 creator A5056300369 @default.
• W2078797427 creator A5072177682 @default.
• W2078797427 creator A5091559601 @default.
• W2078797427 date "2003-12-24" @default.
• W2078797427 modified "2023-10-14" @default.
• W2078797427 title "Pregabalin Add-on Treatment: A Randomized, Double-blind, Placebo-controlled, Dose-Response Study in Adults with Partial Seizures" @default.
• W2078797427 cites W1997048153 @default.
• W2078797427 cites W2005215213 @default.
• W2078797427 cites W2007857430 @default.
• W2078797427 cites W2011913908 @default.
• W2078797427 cites W2016027137 @default.
• W2078797427 cites W2031004040 @default.
• W2078797427 cites W2059212626 @default.
• W2078797427 cites W2073587246 @default.
• W2078797427 cites W2082940913 @default.
• W2078797427 cites W2083311772 @default.
• W2078797427 cites W2103289578 @default.
• W2078797427 cites W2132270420 @default.
• W2078797427 cites W2440035543 @default.
• W2078797427 cites W3017490844 @default.
• W2078797427 cites W4236676256 @default.
• W2078797427 doi "https://doi.org/10.1111/j.0013-9580.2004.31203.x" @default.
• W2078797427 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/14692903" @default.
• W2078797427 hasPublicationYear "2003" @default.
• W2078797427 type Work @default.
• W2078797427 sameAs 2078797427 @default.
• W2078797427 citedByCount "245" @default.
• W2078797427 countsByYear W20787974272012 @default.
• W2078797427 countsByYear W20787974272013 @default.
• W2078797427 countsByYear W20787974272014 @default.
• W2078797427 countsByYear W20787974272015 @default.
• W2078797427 countsByYear W20787974272016 @default.
• W2078797427 countsByYear W20787974272017 @default.
• W2078797427 countsByYear W20787974272018 @default.
• W2078797427 countsByYear W20787974272019 @default.
• W2078797427 countsByYear W20787974272020 @default.
• W2078797427 countsByYear W20787974272021 @default.
• W2078797427 countsByYear W20787974272022 @default.
• W2078797427 crossrefType "journal-article" @default.
• W2078797427 hasAuthorship W2078797427A5020080352 @default.
• W2078797427 hasAuthorship W2078797427A5040362413 @default.
• W2078797427 hasAuthorship W2078797427A5052872325 @default.
• W2078797427 hasAuthorship W2078797427A5054298959 @default.
• W2078797427 hasAuthorship W2078797427A5056300369 @default.
• W2078797427 hasAuthorship W2078797427A5072177682 @default.
• W2078797427 hasAuthorship W2078797427A5091559601 @default.
• W2078797427 hasBestOaLocation W20787974271 @default.
• W2078797427 hasConcept C118552586 @default.
• W2078797427 hasConcept C121332964 @default.
• W2078797427 hasConcept C126322002 @default.
• W2078797427 hasConcept C142424586 @default.
• W2078797427 hasConcept C142724271 @default.
• W2078797427 hasConcept C168563851 @default.
• W2078797427 hasConcept C204787440 @default.
• W2078797427 hasConcept C27081682 @default.
• W2078797427 hasConcept C2775858608 @default.
• W2078797427 hasConcept C2776468701 @default.
• W2078797427 hasConcept C2777803345 @default.
• W2078797427 hasConcept C2778186239 @default.
• W2078797427 hasConcept C2908647359 @default.
• W2078797427 hasConcept C42219234 @default.
• W2078797427 hasConcept C71924100 @default.
• W2078797427 hasConcept C87355193 @default.
• W2078797427 hasConcept C99454951 @default.
• W2078797427 hasConcept C99476002 @default.
• W2078797427 hasConceptScore W2078797427C118552586 @default.
• W2078797427 hasConceptScore W2078797427C121332964 @default.
• W2078797427 hasConceptScore W2078797427C126322002 @default.
• W2078797427 hasConceptScore W2078797427C142424586 @default.
• W2078797427 hasConceptScore W2078797427C142724271 @default.
• W2078797427 hasConceptScore W2078797427C168563851 @default.
• W2078797427 hasConceptScore W2078797427C204787440 @default.
• W2078797427 hasConceptScore W2078797427C27081682 @default.
• W2078797427 hasConceptScore W2078797427C2775858608 @default.
• W2078797427 hasConceptScore W2078797427C2776468701 @default.
• W2078797427 hasConceptScore W2078797427C2777803345 @default.
• W2078797427 hasConceptScore W2078797427C2778186239 @default.
• W2078797427 hasConceptScore W2078797427C2908647359 @default.
• W2078797427 hasConceptScore W2078797427C42219234 @default.
• W2078797427 hasConceptScore W2078797427C71924100 @default.
• W2078797427 hasConceptScore W2078797427C87355193 @default.
• W2078797427 hasConceptScore W2078797427C99454951 @default.
• W2078797427 hasConceptScore W2078797427C99476002 @default.
• W2078797427 hasIssue "1" @default.
• W2078797427 hasLocation W20787974271 @default.
• W2078797427 hasLocation W20787974272 @default.
• W2078797427 hasOpenAccess W2078797427 @default.
• W2078797427 hasPrimaryLocation W20787974271 @default.
• W2078797427 hasRelatedWork W1975953218 @default.
• W2078797427 hasRelatedWork W2024482262 @default.
• W2078797427 hasRelatedWork W2048488699 @default.
• W2078797427 hasRelatedWork W2069354110 @default.

• next